1. Home
  2. DBI vs MOLN Comparison

DBI vs MOLN Comparison

Compare DBI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Designer Brands Inc.

DBI

Designer Brands Inc.

HOLD

Current Price

$7.26

Market Cap

138.7M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.21

Market Cap

164.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DBI
MOLN
Founded
1991
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
138.7M
164.2M
IPO Year
1991
2021

Fundamental Metrics

Financial Performance
Metric
DBI
MOLN
Price
$7.26
$4.21
Analyst Decision
Hold
Hold
Analyst Count
2
1
Target Price
$7.25
$3.75
AVG Volume (30 Days)
1.1M
5.3K
Earning Date
12-09-2025
03-05-2026
Dividend Yield
2.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,892,654,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.70
$999.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$3.36
52 Week High
$8.75
$5.91

Technical Indicators

Market Signals
Indicator
DBI
MOLN
Relative Strength Index (RSI) 52.06 48.81
Support Level $7.64 $4.09
Resistance Level $8.35 $4.31
Average True Range (ATR) 0.54 0.16
MACD -0.13 -0.03
Stochastic Oscillator 23.33 30.78

Price Performance

Historical Comparison
DBI
MOLN

About DBI Designer Brands Inc.

Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: